Many think the next standard cancer treatment will pair two innovations.

An NHS trial over 10 years followed nearly 3,500 men who received focal therapy, a less invasive treatment.

In a phase 2 trial of patients with gastrointestinal cancers, avatrombopag helped 70% of those receiving chemotherapy to stay on treatment schedule, compared with 17% receiving placebo.

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Chemotherapy can save lives, but anyone who has watched a loved one go through it knows how hard it can be. The nausea. The exhaustion. The infections. The days when even getting off the couch feels ...

A cancer drug could enhance how patients respond to chemotherapy even in treatment-resistant tumors. The drug works by disarming a key defense mechanism that tumors use to protect themselves from ...

Chemotherapy is one of the most commonly used treatments for cancer, but it can cause side effects. Alternatives include surgery, targeted therapy, and laser therapy. More than 100 types of cancer ...

Given the prevalence of chewable tobacco products, oral cancer is a significant health concern in India, accounting for about ...

A blood test may help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit from chemotherapy after surgery, according to research presented today at ...

AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.